Jun Gi Hwang

Clinical assistant professor

Chungbuk National University Hospital

South Korea

Research Interests

Explore related searches

Professors in South Korea

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Jun Gi Hwang is a Clinical Assistant Professor at Chungbuk National University Hospital in South Korea. His research primarily focuses on pharmacokinetics and pharmacodynamics, with recent articles discussing novel inhibitors and their effects on renal impairment and metabolic conditions. He has contributed to studies evaluating the safety and tolerability of new pharmaceuticals, including siRNA and biosimilars, emphasizing their application in clinical settings.

Articles (14)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (9)

Sejoong Kim

Seoul National University Hospital

SOUTH KOREA

View details

Soon Kil Kwon

Associate Professor

Chungbuk National University Hospital

SOUTH KOREA

View details

Seung Jae Baek

Chief Medical Officer

SOUTH KOREA

View details

Min-Gul Kim

Professor

Jeonbuk National University Medical School

SOUTH KOREA

View details

Min Kyu Park

SOUTH KOREA

View details

Yun Kim

Assistant Professor

Daegu University

SOUTH KOREA

View details

Kyung-Sang Yu

SOUTH KOREA

View details

Jaeso Cho

Professor

Seoul National University Hospital

SOUTH KOREA

View details

Byungwook Kim

Clinical Professor

Seoul National University Hospital

SOUTH KOREA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jun Gi Hwang

Research Interests

Explore related searches

Contact this professor

About

Articles (14)

A First‐In‐Human Phase 1 Study to Evaluate the Safety and Tolerability of LEM‐S401, a Novel siRNA‐DegradaBALL Drug Targeting CTGF in Healthy Adults

Impact of Renal Impairment on the Pharmacodynamic and Pharmacokinetic Profiles of Epaminurad, a Novel Uric Acid Transporter 1 Inhibitor

Comparison of the pharmacokinetic characteristics and bioequivalence between two nanosuspension formulations of megestrol acetate in healthy Korean male subjects

Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study

The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium‐glucose cotransporter‐2 inhibitor, in type 2 diabetes

Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium–glucose cotransporter 2 inhibitor, with gemigliptin and metformin in healthy adults

Pharmacokinetic and pharmacodynamic interaction between DWP16001, an sodium–glucose cotransporter 2 inhibitor and metformin in healthy subjects

Dose‐dependent glucosuria of DWP16001, a novel selective sodium–glucose cotransporter‐2 inhibitor, in healthy subjects

A double‐blind, placebo‐controlled, single‐ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM15136, a novel long‐acting glucagon analogue, in healthy subjects

Cover Image, Volume 24, Issue 3

Common ABCB1 SNP, C3435T could affect systemic exposure of dapagliflozin in healthy subject

Influence of Renal Function on the Single-Dose Pharmacokinetics of Besifovir, a Novel Antiviral Agent for theTreatment of Hepatitis B Virus Infection.

Pharmacokinetic comparison between tablet of varenicline tartrate and orally disintegrating film of varenicline salicylate in healthy subjects.

Editorial: acid suppression with potassium-competitive acid blockers-dismissing genotype concerns. Authors' reply.

Collaborators (9)

Sejoong Kim

Soon Kil Kwon

Seung Jae Baek

Min-Gul Kim

Min Kyu Park

Yun Kim

Kyung-Sang Yu

Jaeso Cho

Byungwook Kim

Make your next move.